EHA Guidance Document The process of CAR-T cell therapy in Europe
Open Access
- 1 August 2019
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in HemaSphere
- Vol. 3 (4), e280
- https://doi.org/10.1097/hs9.0000000000000280
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- Toxicities of chimeric antigen receptor T cells: recognition and managementBlood, 2016
- Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2016
- Managing critically Ill hematology patients: Time to think differentlyBlood Reviews, 2015
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemiaScience Translational Medicine, 2015
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaBlood, 2015
- Management of relapsed acute lymphoblastic leukemia in childhood with conventional and innovative approachesCurrent Opinion in Oncology, 2013
- Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemiaPediatric Blood & Cancer, 2013
- Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2012
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 2011
- Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group studyLeukemia, 2008